Penile Neoplasms Articles

Articles

  • Contemporary role of radiotherapy in the management of penile cancer.

    Penile cancer is a rare clinical entity that contributes to significant patient morbidity and mortality. Human papilloma virus (HPV) plays an important role in the carcinogenesis of penile squamous cell carcinoma (SCC), is associated with improved clinical outcomes, and is predictive for response to treatment with chemotherapy and radiotherapy.

    Published December 6, 2017
  • HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers

    {{header-clinical-trials-navigation}}

    HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers


    Condition: Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma

    Study Type: Interventional

    Clinical Trials Identifier NCT 8-digits: NCT02379520

    Sponsor: Baylor College of Medicine

    Phase: Phase 1

    Eligibility:

    • Age: minimum 18 Years maximum N/A
    • Gender: All

    Inclusion Criteria:

    • PROCUREMENT 1. Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample 2. Cancer is:
    • recurrent or persistent after standard therapy
    • OR patient is unable to receive standard therapy 3. Karnofsky score ≥ 50% 4. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent TREATMENT 1. Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample 2. Cancer is:
    • recurrent or persistent after standard therapy
    • OR patient is unable to receive standard therapy 3. Life expectancy ≥ 6 weeks. 4. Age ≥ 18 years. 5. Karnofsky score ≥ 50% 6. Bilirubin < 3 × upper limit of normal (ULN), AST < 5 × ULN, Hgb ≥ 7.0 g/dL 7. Pulse oximetry of > 90% on room air. 8. GFR > 30 mL/min calculated by the Cockcroft-Gault, MDRD study, or CKD-EPI creatinine equations, or equivalent 9. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent 10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.

    Exclusion Criteria:

    1. PROCUREMENT
    2. Known HIV positivity. TREATMENT
    3. Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks.
    4. Severe intercurrent infection.
    5. Pregnancy or lactation.

    View trial on ClinicalTrials.gov


    {{footer-clinical-trials-navigation}}
    Published December 22, 2017
  • Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer.

    To determine the impact of lymph node density (LND) on survival after inguinal lymph node dissection (ILND) for penile cancer.

    Our institutional penile cancer database was queried for patients who underwent ILND.

    Published January 26, 2017